Results

1–10 of 230 results for Anti-VEGF

The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
Treatment Patterns and Vision Changes in Anti-VEGF Refractory Diabetic Macular Edema After Dexamethasone Implant in US Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2021
Steroid vs. Anti-VEGF for Diabetic Macular Edema Prior to Phacoemulsification (STAMP)
Caesar K. Luo, MD, FASRS
On Demand Cases, Courses, and Papers
2021
Visual Impact of Central Subfield Thickness (CST) Fluctuation in Patients With nAMD Treated With Anti-VEGFs in VIEW Trials
Dilsher S. Dhoot, MD
On Demand Cases, Courses, and Papers
2021
Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy (FELLOWS FORUM AWARD WINNER)
Lucy T Xu, MD
Annual Meeting Talks
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Matthew Starr, MD
Annual Meeting Talks
2021